Cargando…

Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study

The relationship between gains in bone mineral density (BMD) in the hip and the incidence of vertebral fractures in the MOVER study was examined. Japanese patients from the ibandronate and risedronate treatment groups whose hip BMD had increased during the 3-year treatment period were classified int...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagino, Hiroshi, Yoshida, Seitaro, Hashimoto, Junko, Matsunaga, Masayuki, Tobinai, Masato, Nakamura, Toshitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239781/
https://www.ncbi.nlm.nih.gov/pubmed/25377907
http://dx.doi.org/10.1007/s00223-014-9927-7
_version_ 1782345639941636096
author Hagino, Hiroshi
Yoshida, Seitaro
Hashimoto, Junko
Matsunaga, Masayuki
Tobinai, Masato
Nakamura, Toshitaka
author_facet Hagino, Hiroshi
Yoshida, Seitaro
Hashimoto, Junko
Matsunaga, Masayuki
Tobinai, Masato
Nakamura, Toshitaka
author_sort Hagino, Hiroshi
collection PubMed
description The relationship between gains in bone mineral density (BMD) in the hip and the incidence of vertebral fractures in the MOVER study was examined. Japanese patients from the ibandronate and risedronate treatment groups whose hip BMD had increased during the 3-year treatment period were classified into those with or without vertebral fractures. In both the ibandronate group and the risedronate group, hip BMD gains in the patients who had developed no vertebral fractures during the treatment period were greater than in the patients who developed vertebral fractures. We categorized the gains in hip BMD at 6 months into 3 groups (≤0, >0 to ≤3, and >3 %), and used logistic regression analysis to estimate odds ratios and the probabilities of incidence of vertebral fractures at 12, 24, and 36 months. The current study demonstrated that greater gains in hip BMD during the first 6 months of treatment were associated with a reduction in the risk of subsequent vertebral fractures during the duration of treatment, and suggested that measurement of hip BMD gain at that time could lead to a prediction of the risk of the future vertebral fracture incidence.
format Online
Article
Text
id pubmed-4239781
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-42397812014-11-25 Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study Hagino, Hiroshi Yoshida, Seitaro Hashimoto, Junko Matsunaga, Masayuki Tobinai, Masato Nakamura, Toshitaka Calcif Tissue Int Original Research The relationship between gains in bone mineral density (BMD) in the hip and the incidence of vertebral fractures in the MOVER study was examined. Japanese patients from the ibandronate and risedronate treatment groups whose hip BMD had increased during the 3-year treatment period were classified into those with or without vertebral fractures. In both the ibandronate group and the risedronate group, hip BMD gains in the patients who had developed no vertebral fractures during the treatment period were greater than in the patients who developed vertebral fractures. We categorized the gains in hip BMD at 6 months into 3 groups (≤0, >0 to ≤3, and >3 %), and used logistic regression analysis to estimate odds ratios and the probabilities of incidence of vertebral fractures at 12, 24, and 36 months. The current study demonstrated that greater gains in hip BMD during the first 6 months of treatment were associated with a reduction in the risk of subsequent vertebral fractures during the duration of treatment, and suggested that measurement of hip BMD gain at that time could lead to a prediction of the risk of the future vertebral fracture incidence. Springer US 2014-11-07 2014 /pmc/articles/PMC4239781/ /pubmed/25377907 http://dx.doi.org/10.1007/s00223-014-9927-7 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Research
Hagino, Hiroshi
Yoshida, Seitaro
Hashimoto, Junko
Matsunaga, Masayuki
Tobinai, Masato
Nakamura, Toshitaka
Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study
title Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study
title_full Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study
title_fullStr Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study
title_full_unstemmed Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study
title_short Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study
title_sort increased bone mineral density with monthly intravenous ibandronate contributes to fracture risk reduction in patients with primary osteoporosis: three-year analysis of the mover study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239781/
https://www.ncbi.nlm.nih.gov/pubmed/25377907
http://dx.doi.org/10.1007/s00223-014-9927-7
work_keys_str_mv AT haginohiroshi increasedbonemineraldensitywithmonthlyintravenousibandronatecontributestofractureriskreductioninpatientswithprimaryosteoporosisthreeyearanalysisofthemoverstudy
AT yoshidaseitaro increasedbonemineraldensitywithmonthlyintravenousibandronatecontributestofractureriskreductioninpatientswithprimaryosteoporosisthreeyearanalysisofthemoverstudy
AT hashimotojunko increasedbonemineraldensitywithmonthlyintravenousibandronatecontributestofractureriskreductioninpatientswithprimaryosteoporosisthreeyearanalysisofthemoverstudy
AT matsunagamasayuki increasedbonemineraldensitywithmonthlyintravenousibandronatecontributestofractureriskreductioninpatientswithprimaryosteoporosisthreeyearanalysisofthemoverstudy
AT tobinaimasato increasedbonemineraldensitywithmonthlyintravenousibandronatecontributestofractureriskreductioninpatientswithprimaryosteoporosisthreeyearanalysisofthemoverstudy
AT nakamuratoshitaka increasedbonemineraldensitywithmonthlyintravenousibandronatecontributestofractureriskreductioninpatientswithprimaryosteoporosisthreeyearanalysisofthemoverstudy